The U.S. Food and Drug Administration has approved a new drug to treat a rare form of Amyotrophic Lateral Sclerosis (ALS), also commonly known as Lou Gehrig’s disease. The injectable drug can now be ...

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her disease in its tracks. Raziel Green, 52, an active runner and mother of two, ...

During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With the looming patent cliff, companies are focused on their pipelines and making ...

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by ...

For adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, long-term treatment with tofersen (Qalsody, Biogen) was associated with slowed ...

CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...